Porter Clifton J II
Known title: DirectorCIK: 0001834806
Associated companies
Transaction History
| SBRA | ▲ Buy | Grant | 827 | $0 | 5/30/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 855 | $0 | 2/28/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 748 | $0 | 11/29/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 803 | $0 | 8/30/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 9,480 | $0 | 6/13/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 733 | $0 | 5/31/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 754 | $0 | 2/29/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 700 | $0 | 11/30/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 798 | $0 | 8/31/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 11,382 | $0 | 6/14/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 570 | $0 | 5/31/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 526 | $0 | 2/28/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 473 | $0 | 11/30/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 399 | $0 | 8/31/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 8,751 | $0 | 6/14/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 235 | $0 | 5/31/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 241 | $0 | 2/28/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 243 | $0 | 11/30/2021 | View on chart |
| SBRA | ▲ Buy | Grant | 193 | $0 | 8/31/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Sabra Health Care REIT analysts lower price targets
UBS kept a neutral rating on Sabra Health Care REIT but reduced its price target to $20. Barclays also maintained an equal‑weight stance while cutting its target to $21. Both revisions suggest a more modest outlook for the REIT. The new targets sit near the stock’s recent support level around $19.70.
Sabra Health Care REIT analysts lower price targets. UBS kept a neutral rating on Sabra Health Care REIT but reduced its price target to $20. Barclays also maintained an equal‑weight stance while cutting its target to $21. Both revisions suggest a more modest outlook for the REIT. The new targets sit near the stock’s recent support level around $19.70.